Individual results may vary

"Your pain is real; it is valid, and you
don't have to go through it alone."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Individual results may vary

"Your pain is real; it is valid, and you
don't have to go through it alone."
—Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Contact an Alnylam Patient Education Liaison (PEL)

Our Alnylam Patient Education Liaisons have backgrounds in nursing and are experienced in educating people and their families about matters related to acute hepatic porphyria (AHP). Request an Alnylam PEL to reach out to you and discuss questions you may have about AHP. Submitting a request is quick and easy—simply fill out the form belowYou can also schedule a meeting below.

The purpose of the Alnylam PELs is to provide education to patients, their families, and caregivers. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. PELs do not provide medical care or advice. All diagnosis and treatment decisions should be made by you and your doctor.

 
*Indicates required field

*Please confirm the type of information you would like a Patient Education Liaison to contact you about:

*Please confirm the following so that we may contact you:

Additional (optional) requests:

Schedule a meeting

Schedule a meeting icon

Set up a meeting with an Alnylam PEL to discuss questions you may have about AHP. Submitting a request is quick and easy—click below to schedule a meeting.

 

IMPORTANT SAFETY INFORMATION

Do not use GIVLAARI® (givosiran) if you have ever had a severe allergic reaction to GIVLAARI.

  • Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:

    • Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
    • Breathing problems or wheezing
    • Feeling dizzy or fainting
    • Rash or hives
    • Itching

    If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

  • Your doctor will check your liver function by doing blood tests:

    • Before you start using GIVLAARI
    • Once a month for the first 6 months of treatment
    • And when they think it is needed

    If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

  • Your doctor will check how your kidneys are working while you are using GIVLAARI.

  • GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

    Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

  • GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

  • Cases of acute pancreatitis including some that were severe, have been reported in patients receiving GIVLAARI. If you have a severe case of acute pancreatitis your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-8 00-FDA -1088.


WHAT IS GIVLAARI?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.


For additional information about GIVLAARI, please see full Prescribing Information.